WO2018151245A1 - Composition et procédé favorisant la production d'interleukine-23 - Google Patents
Composition et procédé favorisant la production d'interleukine-23 Download PDFInfo
- Publication number
- WO2018151245A1 WO2018151245A1 PCT/JP2018/005414 JP2018005414W WO2018151245A1 WO 2018151245 A1 WO2018151245 A1 WO 2018151245A1 JP 2018005414 W JP2018005414 W JP 2018005414W WO 2018151245 A1 WO2018151245 A1 WO 2018151245A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interleukin
- cells
- production
- lactobacillus
- promoting
- Prior art date
Links
- 230000001737 promoting effect Effects 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 230000003704 interleukin-23 production Effects 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 21
- 241000894006 Bacteria Species 0.000 claims abstract description 56
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 21
- 241000186606 Lactobacillus gasseri Species 0.000 claims abstract description 20
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 18
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 15
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 14
- 241001468157 Lactobacillus johnsonii Species 0.000 claims abstract description 14
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 100
- 210000004027 cell Anatomy 0.000 claims description 88
- 108010065637 Interleukin-23 Proteins 0.000 claims description 58
- 102000013264 Interleukin-23 Human genes 0.000 claims description 58
- 239000004310 lactic acid Substances 0.000 claims description 50
- 235000014655 lactic acid Nutrition 0.000 claims description 50
- 229940124829 interleukin-23 Drugs 0.000 claims description 42
- 210000004443 dendritic cell Anatomy 0.000 claims description 35
- 238000004519 manufacturing process Methods 0.000 claims description 27
- 230000000813 microbial effect Effects 0.000 claims description 23
- 241000186000 Bifidobacterium Species 0.000 claims description 20
- 230000001580 bacterial effect Effects 0.000 claims description 19
- 238000001727 in vivo Methods 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 abstract description 17
- 229940072205 lactobacillus plantarum Drugs 0.000 abstract description 17
- 239000000796 flavoring agent Substances 0.000 abstract description 3
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 230000004075 alteration Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 241000186660 Lactobacillus Species 0.000 description 47
- 229940039696 lactobacillus Drugs 0.000 description 47
- 235000013305 food Nutrition 0.000 description 36
- 239000000047 product Substances 0.000 description 26
- 244000005700 microbiome Species 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940127557 pharmaceutical product Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 235000015140 cultured milk Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 150000002763 monocarboxylic acids Chemical class 0.000 description 3
- -1 royal jelly Chemical class 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 241001455214 Acinonyx jubatus Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 241000289619 Macropodidae Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 241000283203 Otariidae Species 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000282335 Procyon Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 101100412401 Rattus norvegicus Reg3a gene Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Chemical group 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Chemical group 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001746 carotenes Chemical group 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Chemical group CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Chemical group 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Chemical group 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Definitions
- the present invention relates to a composition for promoting production of interleukin-23, a method for promoting production of interleukin-23, and the like.
- IL interleukin-23 secretion (production) promoter comprising a low molecular weight monocarboxylic acid such as acetic acid, lactic acid or thioglycolic acid
- low molecular weight monocarboxylic acids such as acetic acid, lactic acid or thioglycolic acid have a relatively strong acidity and are difficult to take as they are. For this reason, in order to ingest a low molecular weight monocarboxylic acid without a sense of incongruity, processing such as formulation is required. Specifically, a troublesome work such as adding a sweetener or the like to change the taste or encapsulating is required.
- An object of the present invention is to provide an IL-23 production promoter, a composition for promoting IL-23 production, and the like that can save troublesome work such as changing taste and encapsulating.
- the composition for promoting IL-23 production according to the first aspect of the present invention contains bacterial cells as an active ingredient. That is, the bacterial cells are used as a composition for promoting IL-23 production or as a component thereof.
- a microbial cell may be a living microbial cell or a dead microbial cell. When the cells are dead cells, the dead cells are preferably heat-killed cells, that is, cells killed by heat.
- the “composition” referred to herein includes animals such as pharmaceuticals, supplements and food additives, foods and drinks (excluding animals and plants themselves), and food and drink compositions (including processed foods and drinks). Included are those that can be ingested (including humans).
- the bacterial cells according to the first aspect of the present invention can promote the production of IL-23. That is, this microbial cell can favorably promote the production of IL-23.
- IL-23 acts on ILC3 to induce the production of IL-22.
- IL-22 is recognized by small intestinal epithelial cells, expression of antibacterial peptides such as Reg3 family proteins is induced. And, microorganisms such as foreign bacteria are killed by this antibacterial peptide, and expansion of microbial infection and excessive inflammatory reaction can be suppressed.
- This effect is only an example, and it can be sufficiently assumed that IL-23 induces the production of other substances and other effects are manifested.
- this microbial cell is tasteless. Therefore, when preparing the composition for promoting production of IL-23, troublesome work such as changing the taste and encapsulating can be saved. Of course, the taste of the composition for promoting production of IL-23 may be changed from other viewpoints, or the composition for promoting production of IL-23 may be encapsulated.
- the microbial cells are preferably at least one of lactic acid bacteria and bifidobacteria.
- lactic acid bacteria are Lactobacillus delbrueckiispsubsp. Bulgaricus, Lactobacillus gasseri, Streptococcus thermophilus (Streptococcus). It is preferably at least one lactic acid bacterium selected from the group consisting of thermophilus, Lactobacillus plantarum and Lactobacillus johnsonii.
- lactic acid bacteria are “Lactobacillus delbrucky subspecies bulgaricus 2038, Lactobacillus delbrucky subspecies bulgaricus OLL1181 (Accession number: FERM BP- 11269), Lactobacillus delbrucky subspecies bulgaricus OLL1255 (Accession number: NITE BP-76), Lactobacillus delbrucky subspecies bulgaricus OLL1073R-1 (accession number: FERM BP-10741), lact Bacillus gasseri OLL2716 (Accession number: FERM BP-6999), Lactobacillus gaseri OLL2809 (Accession number: NITE BP-72), Lactobacillus gaseri OLL2 59 (Accession number: NITE BP-224), Lactobacillus plantarum OLL 2712 (Accession number: FERM BP
- Lactobacillus delbruecki Subspecies Bulgarix OLL1255 (Accession number: NITE BP-76), Lactobacillus gaseri OL More preferably, it is at least one lactic acid bacterium selected from the group consisting of L2959 (Accession Number: NITE BP-224), Lactobacillus plantarum OLL2712 (FERM BP-11262), and Streptococcus thermophilus 1131.
- the bifidobacteria is preferably Bifidobacterium bifidum.
- Bifidobacterium is preferably Bifidobacterium bifidum OLB6378 (accession number: NITE BP-31).
- the dendritic cells are tsDC, among the above-mentioned cells, cells that produce interleukin-23 at a concentration of 30 pg / mL or higher with respect to tsDC are preferable, and interleukins at a concentration of 50 pg / mL or higher are preferable. More preferably, microbial cells producing -23, more preferred microbial cells producing interleukin-23 at a concentration of 70 pg / mL or more, particularly preferred microbial cells producing interleukin-23 at a concentration of 90 pg / mL or more. .
- the dendritic cell when the dendritic cell is tsDC, specifically, Lactobacillus delbruecki subspecies bulgaricus that produces interleukin-23 at a concentration of 30 pg / mL or more with respect to tsDC.
- the dendritic cells are BMDC
- cells that produce interleukin-23 at a concentration of 300 pg / mL or higher relative to BMDC are preferable, and interleukins at a concentration of 600 pg / mL or higher are preferable.
- cells producing -23 more preferably cells producing interleukin-23 at a concentration of 900 pg / mL or more, more preferably cells producing interleukin-23 at a concentration of 1200 pg / mL or more.
- Cells that produce interleukin-23 at a concentration of 1500 pg / mL or more are more preferred, and cells that produce interleukin-23 at a concentration of 2000 pg / mL or more are particularly preferred.
- the dendritic cell is BMDC
- Lactobacillus delbrukee subspecies bulgaricus that produces interleukin-23 at a concentration of 800 pg / mL or more with respect to BMDC
- Lactobacillus delbruecki subspecies bulgaricus producing interleukin-23 at a concentration of 1000 pg / ml or more Lactobacillus delbruecki subspecies bulgaric producing interleukin-23 at a concentration of 1300 pg / ml or more Lactobacillus delbruecki subspecies bulgaricus producing interleukin-23 at a concentration of 1600 pg / ml or more
- Streptococcus producing interleukin-23 at a concentration of 2000 pg / ml or more S.
- thermophilus Lactobacillus gasseri that produces interleukin-23 at a concentration of 800 pg / mL or more, Lactobacillus gasseri that produces interleukin-23 at a concentration of 1000 pg / mL, or 1300 pg / mL or higher Lactobacillus gasseri that produces leukin-23, Lactobacillus gasseri that produces interleukin-23 at a concentration of 1600 pg / ml or more, Lactobacillus plantarum that produces interleukin-23 at a concentration of 1000 pg / ml or more, Lactobacillus plantarum producing interleukin-23 at a concentration of 1500 pg / mL or higher, Lactobacillus johnsonii producing interleukin-23 at a concentration of 300 pg / mL or higher, 800 pg / m Lactobacillus johnsonii producing interleuk
- the method according to the second aspect of the present invention is a method of using bacterial cells as an IL-23 production promoter. That is, to provide a microbial cell for use as an IL-23 production promoter.
- the method according to the third aspect of the present invention is a method of promoting IL-23 production in vivo by orally administering the above-mentioned composition for promoting IL-23 production.
- the administration period is preferably 1 week or more, more preferably 2 weeks or more, further preferably 3 weeks or more, and particularly preferably 4 weeks or more.
- the bacterial cells are brought into contact with dendritic cells. That is, the bacterial cells are brought into contact with dendritic cells to promote IL-23 production.
- the use of the bacterial cell according to the fourth aspect of the present invention is an act for producing a composition for promoting the production of IL-23.
- FIG. 3 is a bar graph showing IL-23 secretion amount (pg / mL) when tsDC is stimulated with various lactic acid bacteria heated dead cells.
- FIG. 3 is a bar graph showing IL-23 secretion amount (pg / mL) when BMDC is stimulated with various lactic acid bacteria killed by heating.
- FIG. 3 is a bar graph showing IL-23 secretion amount (pg / mL) when BMDC was stimulated with various lactic acid bacteria and Bifidobacterium heat-killed cells.
- the composition for promoting IL-23 production contains microbial cells as an active ingredient.
- the bacterial cell may be a live cell or a dead cell.
- the dead cells are preferably heat-killed cells.
- the term “heat-dead cell” is an object after the cell is killed by heating.
- this IL-23 production promoting composition may consist only of microbial cells or may contain other components.
- microbial cells can include, for example, lactic acid bacteria, bifidobacteria, and the like. Lactic acid bacteria are a general term for taxonomically recognized lactic acid bacteria or all related bacteria, and there are no restrictions on bacterial species or strains.
- bifidobacteria is a generic term for taxonomically recognized bifidobacteria or all of the related bacteria, and there is no restriction on the bacterial species or strains.
- lactic acid bacteria may be classified into plant origin and animal origin depending on their origin, the lactic acid bacteria of the present invention can be used from both plant origin and animal origin.
- the lactic acid bacteria are Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus gasseri, Streptococcus thermophilus (Streptococcus ⁇ ⁇ ⁇ thermophilus), More preferably, it is at least one lactic acid bacterium selected from the group consisting of Lactobacillus plantarum and Lactobacillus johnsonii.
- Lactobacillus delbruecki subspecies bulgaricus Lactobacillus delbrucky subspecies bulgaricus 2038, Lactobacillus delbrucky subspecies bulgaricus OLL1181 (Accession number: FERM BP- 11269), Lactobacillus delbruecki subspecies bulgaricus MEP201701, Lactobacillus delbrucky subspecies bulgaricus OLL1255 (Accession number: NITE BP-76), Lactobacillus delbrucky subspecies bulgaricus OLLG1073R -1 (accession number: FERM BP-10741), and in the case of Lactobacillus gasseri, Re-OLL 2716 (Accession number: FERM BP-6999), Lactobacillus gaselli OLL2809 (Accession number: NITE BP-72), Lactobacillus gaseri OLL2959 (Accession
- the Bifidobacterium is preferably Bifidobacterium bifidum.
- the Bifidobacterium bifidum is preferably Bifidobacterium bifidum OLB6378 (Accession number: NITE BP-31), Bifidobacterium bifidum MEP201804.
- Lactobacillus delbruecki subspecies bulgaricus 2038 can be obtained by isolating it from Bulgarian yogurt LB81 (registered trademark) manufactured by Meiji Co., Ltd. by a usual method.
- Lactobacillus delbruecki subspecies bulgaricus MEP201701 can be obtained by isolation from fermented milk from the Republic of Bulgaria by a conventional method.
- Lactobacillus delbruecki Subspecies Bulgarix OLL1255 was issued on February 10, 2005 (original deposit date), and is based on the Patent Microorganism Depositary Center of the National Institute of Technology and Evaluation (Kazusa Kama, Kisarazu City, Chiba Prefecture, Japan).
- NITE BP-76 has been deposited internationally under the Budapest Treaty (transferred from the original deposit to the deposit under the Budapest Treaty on April 1, 2009).
- Lactobacillus delbruecki Subspecies Bulgarix OLL1073R-1 was established on February 22, 1999 (date of domestic consignment), National Institute of Advanced Industrial Science and Technology, Biological Depositary Center (East 1 in Tsukuba City, Ibaraki Prefecture, Japan) No. 1 Chome No. 1 (Chuo No. 6) (later centralized in the Patent Microorganism Deposit Center of the National Institute of Technology and Evaluation (Kazusa-Kamazu 2-5-8, No.
- Lactobacillus gaselli OLL2716 was dated May 24, 1999 (original deposit date), and the Institute of Biotechnology, Institute of Industrial Technology, Ministry of International Trade and Industry (1-3 Higashi 1-chome, Tsukuba, Ibaraki, Japan) Independent administrative agency, Product Evaluation Technology Foundation, Patent Microorganism Deposit Center (Centralized in Room 122, 2-5-8, Kazusa Kamashizu, Kisarazu City, Chiba, Japan), under the accession number: FERM BP-6999, based on the Budapest Treaty Deposited (transferred from the original deposit to the deposit under the Budapest Treaty on January 14, 2000).
- Lactobacillus gaselli OLL2809 dated February 1, 2005 (original deposit date), is the Patent Microorganisms Depositary Center for Product Evaluation Technology, Japan (2-5-8 Kazusa Kamashi, Kisarazu City, Chiba Prefecture, Japan) 122 Room No.) has been deposited internationally under the Budapest Treaty under the deposit number: NITE BP-72 (transferred from the original deposit to the deposit under the Budapest Treaty on January 18, 2006).
- Lactobacillus gaselli OLL2959 dated March 31, 2006 (original deposit date), National Institute for Product Evaluation Technology Patent Microorganisms Deposit Center (2-5-8 Kazusa Kamashika, Kisarazu City, Chiba Prefecture, Japan) 122 No.
- Lactobacillus gasseri MEP201801 can be obtained by isolation from normal feces of healthy adults by conventional methods.
- Streptococcus thermophilus 1131 can be obtained by isolation from Bulgarian yogurt LB81 (registered trademark) manufactured by Meiji Co., Ltd. according to a conventional method.
- Streptococcus thermophilus MEP201702 can be isolated and obtained from fermented milk from the Republic of Bulgaria by a conventional method.
- Lactobacillus plantarum OLL 2712 was issued on July 2, 2010, National Institute of Advanced Industrial Science and Technology, Biological Depositary Center (1st, 1st East, 1-chome, Tsukuba, Ibaraki, Japan) Incorporated internationally under the Budapest Treaty under the accession number: FERM BP-11262, which is centralized in the Patent Product Depositary Center of the National Institute for Product Evaluation and Technology (centralized at 2-5-8, Kazusa-Kamashita 2-5-8, Kisarazu City, Chiba, Japan) Yes. Lactobacillus plantarum MEP201802 can be obtained by isolation from raw milk from Hokkaido by a conventional method.
- Lactobacillus johnsonii OLL203565 was issued on February 3, 2015 at the Japan Institute for Product Evaluation Technology Patent Microorganism Depositary Center (Kazusa Kamashichi, Kisarazu City, Chiba Prefecture, 2-5-8, Room 122). Deposit number: NITE BP-02003 is deposited internationally based on the Budapest Treaty.
- Lactobacillus johnsonii OLL204255 was issued on February 3, 2015 in the National Institute for Product Evaluation Technology Patent Microorganism Depositary Center (Room 2-5-8, Kazusa Kamashichi, Kisarazu City, Chiba, Japan). Deposit number: NITE BP-02004 is deposited internationally based on the Budapest Treaty.
- Lactobacillus johnsonii MEP201803 can be obtained by isolation from a dogwood pod that inhabits the mountains of Kanagawa Prefecture by a conventional method.
- Bifidobacterium bifidum OLB6378 was commissioned on October 26, 2004 by the National Institute for Product Evaluation Technology Patent Microorganisms Deposit Center (2-5-8 Kazusa Kamashika, Kisarazu City, Chiba Prefecture, Japan). Number: NITE BP-31 is deposited internationally based on the Budapest Treaty.
- Bifidobacterium bifidum MEP201804 can be obtained by isolation from healthy adult feces by conventional methods.
- the form of the cells can be used even if it is frozen or freeze-dried.
- the microbial cells may be in a form in which only the microbial cells or components other than the microbial cells (for example, cryoprotectants, lyophilization protectants, etc.) are included.
- it may be dispersed in various media such as starch and water that have been used.
- the IL-23 production promoting composition according to the embodiment of the present invention exhibits its function when taken by mammals including humans.
- the “intake” as used herein is not limited to the administration route as long as it enters the human body, and is realized by all known administration methods such as oral administration, tube administration, enteral administration and the like. obtain. In this case, typical examples include oral intake and enteral intake via the digestive tract, but oral intake is preferable, and intake by eating and drinking is more preferable.
- the composition for promoting IL-23 production according to the embodiment of the present invention may be any microorganism as long as it contains bacteria, and the number thereof is not particularly limited, but there are 100 million or more bacteria per unit package. Preferably, 500,000 or more are present, more preferably 1 billion or more. The effect can be expected as the number of cells increases, but the upper limit is 10 trillion.
- the weight per unit packaging of the IL-23 production promoting composition according to the embodiment of the present invention is not particularly limited, but when there are 100 million or more cells per gram of the IL-23 production promoting composition,
- the weight is preferably in the range of 10 to 500 g, more preferably in the range of 25 to 250 g, more preferably in the range of 50 to 200 g, and in the range of 75 to 150 g. Most preferably.
- the above-mentioned unit packaging is not limited to unit packaging per bag, box, and container, but may be unit packaging per one time included therein or unit packaging per day. It should be noted that a plurality of days, for example, a quantity suitable for intake for one week may be packaged together, or may include a plurality of individual packages.
- the composition for promoting IL-23 production is desirably ingested continuously for 3 weeks or more, preferably 5 weeks or more, more preferably 8 weeks or more.
- the ingestion period is not particularly limited and can be permanently continued. From the viewpoint of obtaining a sufficiently effective IL-23 production effect, the intake period is preferably 8 weeks.
- the composition for promoting IL-23 production according to the embodiment of the present invention can be used as a pharmaceutical or a food or drink.
- the medicinal product or food or drink is useful in that it has an IL-23 production promoting effect, and can be used, for example, as a medicinal product or food or drink for preventing or treating microbial infection.
- the composition for promoting IL-23 production according to the embodiment of the present invention is used as a pharmaceutical product or a food or drink, the cells of a single strain may be used, or the cells of two or more strains may be used. You may use it in combination.
- the state of the IL-23 production promoting composition is not limited, and it is a pasty product, a spray-dried product, or a freeze-dried product.
- the product can be used in the form of a product, a vacuum dried product, a drum dried product, a liquid product dispersed in a medium, a diluted product diluted with a diluent, a crushed product obtained by crushing a dried product with a mill or the like.
- the composition for promoting IL-23 production according to the embodiment of the present invention can be used as a health functional food or a food for the sick.
- the functional health food system is intended for not only regular foods but also foods in the form of tablets, capsules, etc., taking into account trends in Japan and overseas and the consistency with conventional food systems for specified health use. .
- two types of foods for specific health use (individual permission type) and functional foods (standard specification type) are defined.
- the composition for promoting production of IL-23 according to the embodiment of the present invention is administered to animals such as humans as special-purpose foods such as foods for specified health use or nutritional functional foods, thereby preventing various infections, for example. Is possible.
- the IL-23 production promoting composition it is preferable to display a description of its use, efficacy, function, type of active ingredient, type of functional ingredient, ingestion method, and the like.
- “Indication” as used herein refers to pharmaceuticals, quasi drugs, health functional foods, foods for specified health use, functional foods for nutrition, general foods, health supplements, health foods, supplements, enteral nutrition, oral cosmetics, and feed Each should be a suitable display.
- the “display” here includes all displays for informing the consumer of the above description.
- This display only needs to be a display that allows the above-described display contents to be recalled / analogized, and may include any display regardless of the purpose of display, the display contents, the object / medium to be displayed, and the like. For example, display the above description on product packaging / containers, display the above description on product advertisements / price lists or transaction documents, or display or distribute the information, electromagnetically (such as the Internet) ) By a method.
- the product obtained by packaging the composition for promoting IL-23 production is, for example, a food or drink
- the food or drink includes, for example, an indication “for IL-23 production promotion”
- the label “contains lactic acid bacteria that promotes the production of IL-23”, the label “for antibacterial peptide enhancement”, the label “for prevention of infectious diseases”, etc. Is preferred.
- the wording used for the display as described above is not limited to the above-described example, and may be a word having the same meaning as that.
- various terms that allow the consumer to recognize IL-23 production promotion, antibacterial peptide enhancement, infection prevention effects, and the like can be accepted.
- the type of the food or drink is not particularly limited.
- Foods and beverages include, for example, milk, processed milk, soft drinks, fermented milk, yogurt, cheese, other dairy products, bread, biscuits, crackers, pizza crusts, prepared powdered milk, liquid food, food for the sick, infant milk powder, etc. It may be food, food such as powdered milk for pregnant women and lactating women, and nutritional food.
- the bacterial cells that are the active ingredients of the IL-23 production promoting composition according to the embodiment of the present invention are used as they are, or mixed with other foods and drinks or food ingredients.
- the manufacturing method in a normal food composition can be used. Moreover, it does not specifically limit about the shape of food / beverage products, The shape of food / beverage products used normally may be sufficient. For example, any shape such as solid (including powder and granule), paste, liquid, and suspension may be used, but not limited thereto. At this time, milk drink, fermented milk, soft drink, jelly drink, tablet, and powdered food are more preferable, and yogurt is more preferable.
- the cells that are active ingredients of the composition for promoting IL-23 production according to the embodiment of the present invention include water, protein, carbohydrate, lipid, vitamins, minerals, organic acid, organic base, fruit juice, and flavor. As long as it is a component contained in normal foods such as functional ingredients and food additives, it can be added without any problem.
- protein sources for example, whole milk powder, skim milk powder, partially skim milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -Uses proteins or protein-containing raw materials commonly used in food production, such as casein, ⁇ -lactoglobulin, ⁇ -lactalbumin, lactoferrin, soy protein, chicken egg protein, meat protein, and other hydrolysates can do.
- sugar sources include processed starch (in addition to text phosphorus, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
- Examples of the lipid source include animal oils such as lard and fish oil, fractionated oils thereof, hydrogenated oil and transesterified oil; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, and fractionated oils thereof. And vegetable oils such as hydrogenated oil and transesterified oil.
- vitamins include vitamin A, carotenes, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline.
- Examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium.
- Examples of the organic acid include malic acid, citric acid, lactic acid, and tartaric acid.
- Examples of the functional component include oligosaccharide, glucosamine, collagen, ceramide, royal jelly, polyphenol and the like.
- Examples of food additives include emulsifiers, stabilizers, thickeners, gelling agents, sweeteners, acidulants, preservatives, antioxidants, pH adjusters, and colorants.
- Various milk-derived components such as butter, dairy minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, and lactose can be suitably used for the production of the food and drink according to the embodiment of the present invention. It is an example.
- the raw material may be any of natural products, processed natural products, synthetic products and / or foods containing a large amount thereof.
- the bacterial cell that is the active ingredient of the composition for promoting IL-23 production according to the embodiment of the present invention can be used as a drug for preventing infection or a drug for treatment.
- the bacterial cell can be used as a crushed or unground product.
- the microbial cell to be used may be single or multiple types.
- the amount of bacterial cells in the above pharmaceutical product can be arbitrarily determined according to the purpose and application (prophylactic agent, therapeutic agent, etc.).
- An example of the content may be 0.001 to 100% (w / w), particularly 0.1 to 100%, based on the total amount, but the present invention is not limited to this.
- the dosage of the pharmaceutical agent containing the above bacterial cells as an active ingredient can be appropriately set in consideration of various factors such as the administration route, the age, weight, and symptoms of animals to be administered including humans.
- a suitable dose 1 to 1000 mg / kg / day can be mentioned as an active ingredient, but the present invention is not limited to this.
- the amount when ingested for preventive purposes over a long period, the amount may be smaller than the above range.
- this active ingredient since this active ingredient has no safety problem, it can be used in a larger amount than the above range.
- the above-mentioned pharmaceutical dosage form is preferably a dosage form that can be administered orally in order to allow the cells of the present invention to reach the intestine.
- Examples of preferable dosage forms of the pharmaceutical product according to the present invention include tablets, coated tablets, capsules, granules, powders, liquids, syrups, lozenges and the like.
- These various preparations are prepared according to conventional methods, such as excipients, binders, disintegrants, lubricants, coloring agents, flavoring agents, solubilizing agents, suspension agents, coating agents, etc. It can be formulated by mixing adjuvants that can be usually used in the pharmaceutical preparation technical field.
- the microbial cells can be administered (ingested) as they are.
- the microbial cells can be administered (ingested) as they are.
- tablets, granules, powders Can be used as a capsule or powder.
- the composition for promoting the production of IL-23 according to the embodiment of the present invention can be expected to exhibit effects at all sites of the digestive tract.
- the digestive tract is a site including a series of oral cavity, pharynx, esophagus, stomach, duodenum, small intestine, large intestine, cecum, and anus.
- typical names of the digestive tract are illustrated.
- the colon lower small intestine
- ileum jejunum
- upper abdominal digestive tract lower abdominal digestive tract
- large intestine lower large intestine
- the composition for promoting IL-23 production according to the embodiment of the present invention is effective for all mammals including humans. Therefore, various diseases can be treated or prevented by ingesting and / or administering this IL-23 production promoting composition.
- Mammals as used herein include humans, cows, pigs, sheep, dolphins, whales, tigers, lions, cheetahs, hippos, giraffes, camels, alpaca, dogs, cats, monkeys, foxes, raccoons, bears, squirrels, fur seals , Sea lions, pandas, wild boars, deer, horses, orangutans, kangaroos, etc., which are all known livestock, pets, appreciation animals, wild animals and the like and classified as mammals.
- the composition for promoting IL-23 production according to the embodiment of the present invention is also applied to animals having a digestive tract, such as insects, reptiles, birds, fishes, amphibians, molluscs and the like. Administration and / or ingestion is also possible, and it is expected that the same effects as described above can be obtained.
- the various diseases referred to herein are not particularly limited, and may be any diseases that can be treated and / or prevented by inducing an antibacterial peptide, for example.
- diseases include infections caused by opportunistic bacteria, infections caused by pathogenic bacteria and fungi, infections caused by Helicobacter pylori, bacterial translocation, persistent intestinal mucosal inflammation, and changes in the balance of intestinal flora (intestinal Internal flora balance), diseases induced by these inflammations, Crohn's disease, inflammatory colitis such as ulcerative colitis, excessive inflammation and allergic symptoms that induce differentiation of regulatory T cells It is done.
- Example 1 Preparation of heat-killed lactic acid bacteria
- Bulgaricus 2038 Lactobacillus delbrueckii subsp.
- Bulgaricus MEP201701 Lactobacillus delbrueckii subsp.
- Bulgaricus OLL1255 (Accession number: NITE BP-76) ⁇ Lactobacillus delbrueckii subsp.
- each medium was washed with phosphate buffered saline (PBS). And the turbidity of the washing
- cleaning liquid was measured with wavelength 650nm with the spectrophotometer, and lactic acid bacteria suspension was prepared so that OD might be set to 2. Finally, each lactic acid bacterium suspension was incubated in a 65 ° C. hot water bath for 1 hour to prepare a target lactic acid bacterium heat-killed cell.
- PBS phosphate buffered saline
- BMDC bone marrow-derived dendritic cells
- auto MACS registered trademark
- Balb / c mice 8-week-old male Balb / c mice (provided by SLC, Japan)
- GM-CSF granulocyte macrophage colony-stimulating factor
- tsDC When tsDC is used as a dendritic cell, all of the nine strains of lactic acid bacteria are used.
- BMDC When a dendritic cell, the nine strains of lactic acid bacteria are used. Among them, only heat-killed cells of Lactobacillus delbruecki subspecies bulgaricus 2038 and Streptococcus thermophilus 1131 were used.
- Control sample preparation Dendritic cells were seeded in a 24-well plate so that the dendritic cells were 1 ⁇ 10 5 cells / well and the liquid volume was 500 ⁇ L, and the next day, 5 ⁇ L of phosphate buffered saline (PBS) was added to each well. ) was added. Thereafter, tsDC dendritic cells were cultured for 24 hours at 33 ° C. in a 9% CO 2 environment, and BMDCs were incubated for 24 hours at 37 ° C. in a 5% CO 2 environment. At this time, three samples were prepared for each of tsDC dendritic cells and BMDC. And the supernatant was collect
- PBS phosphate buffered saline
- Example 2 Preparation of heat-killed cells
- 11 strains of lactic acid bacteria and 2 strains of bifidobacteria were prepared.
- Bulgaricus OLL1073R-1 accesion number: FERM BP-10741
- Bulgaricus OLL1181 accesion Number: FERM BP-11269
- each medium was stored in a jar containing an anero pack, and each lactic acid bacterium and bifidobacteria were activated and cultured once at 37 ° C. in an anaerobic environment.
- each medium was washed with phosphate buffered saline (PBS). Then, the turbidity of the washing solution was measured with a spectrophotometer at a wavelength of 650 nm, and a lactic acid bacterium suspension and a bifidobacteria suspension were prepared so that the OD was 2.
- PBS phosphate buffered saline
- each lactic acid bacterium suspension and bifidobacteria suspension were incubated in a hot water bath at 65 ° C. for 1 hour to prepare target lactic acid bacterium heated dead cells and bifidobacteria heated dead cells.
- BMDC bone marrow-derived dendritic cells
- Control sample preparation A control sample was prepared according to the same procedure as described in “4. Preparation of Control Sample” in Example 1.
- composition for promoting production of interleukin-23 according to the present invention can save troublesome work such as changing the taste and encapsulating, and can be produced at low cost.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La présente invention concerne une composition favorisant la production d'interleukine-23 qui permet d'éliminer des procédures lourdes telles que l'encapsulation et la modification d'arôme. La composition favorisant la production d'interleukine-23 selon la présente invention contient des bactéries à titre de principe actif. Les bactéries à utiliser sont de préférence d'au moins un type choisi dans le groupe constitué par Lactobacillus delbrueckii ssp. Bulgaricus, Lactobacillus gasseri, Streptococcus thermophilus, Lactobacillus plantarum, Lactobacillus johnsonii, et Bifidobacterium bifidum.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018568622A JP7531261B2 (ja) | 2017-02-17 | 2018-02-16 | インターロイキン-23産生促進用組成物 |
JP2024100172A JP2024111238A (ja) | 2017-02-17 | 2024-06-21 | インターロイキン-23産生促進用組成物およびReg3ファミリータンパク質の発現誘導用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017027416 | 2017-02-17 | ||
JP2017-027416 | 2017-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018151245A1 true WO2018151245A1 (fr) | 2018-08-23 |
Family
ID=63169927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/005414 WO2018151245A1 (fr) | 2017-02-17 | 2018-02-16 | Composition et procédé favorisant la production d'interleukine-23 |
Country Status (2)
Country | Link |
---|---|
JP (2) | JP7531261B2 (fr) |
WO (1) | WO2018151245A1 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010099024A (ja) * | 2008-10-24 | 2010-05-06 | Technical Research & Development Institute Ministry Of Defence | 抗炎症効果を有する新規植物性乳酸菌株、該菌株を用いた炎症性腸疾患又は慢性下痢症に対する予防及び治療剤、抑制剤並びに添加剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX336030B (es) | 2009-05-11 | 2016-01-07 | Nestec Sa | Lactobacillus johnsonii la1 mcc533 (cncm i-1225) y padecimientos inmunes. |
WO2011145737A1 (fr) | 2010-05-21 | 2011-11-24 | 株式会社明治 | Composition pour améliorer l'état de la peau |
TWI572354B (zh) | 2010-09-09 | 2017-03-01 | 明治股份有限公司 | 抑制發炎之組成物 |
WO2015087919A1 (fr) | 2013-12-10 | 2015-06-18 | 株式会社明治 | Agent inducteur de peptide antibactérien |
TW201701891A (zh) | 2015-02-27 | 2017-01-16 | Meiji Co Ltd | 大腸炎抑制劑 |
-
2018
- 2018-02-16 WO PCT/JP2018/005414 patent/WO2018151245A1/fr active Application Filing
- 2018-02-16 JP JP2018568622A patent/JP7531261B2/ja active Active
-
2024
- 2024-06-21 JP JP2024100172A patent/JP2024111238A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010099024A (ja) * | 2008-10-24 | 2010-05-06 | Technical Research & Development Institute Ministry Of Defence | 抗炎症効果を有する新規植物性乳酸菌株、該菌株を用いた炎症性腸疾患又は慢性下痢症に対する予防及び治療剤、抑制剤並びに添加剤 |
Non-Patent Citations (6)
Also Published As
Publication number | Publication date |
---|---|
JPWO2018151245A1 (ja) | 2019-12-12 |
JP7531261B2 (ja) | 2024-08-09 |
JP2024111238A (ja) | 2024-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10925906B2 (en) | Composition for improving brain function for neonates | |
JPWO2007020884A1 (ja) | β−ディフェンシンを介した感染予防効果を有するビフィズス菌または乳酸菌とそれを含有する食品・医薬品組成物 | |
US20190240268A1 (en) | Infection protective agent for infants | |
KR20180129945A (ko) | 제지방 체중을 증가시키기 위한 비피더스균 | |
US20190201459A1 (en) | Anti-allergic agent for infants | |
WO2019182160A1 (fr) | Composition pour améliorer un constituant de lait maternel | |
WO2018190407A1 (fr) | COMPOSITION PERMETTANT D'ACTIVER UN RÉCEPTEUR DE TYPE Toll 2 | |
WO2018225786A1 (fr) | Composition pour l'activation de l'immunité cellulaire | |
WO2015087919A1 (fr) | Agent inducteur de peptide antibactérien | |
US11638431B2 (en) | Fermented milk and polysaccharide with cancerous cachexia inhibitory effect | |
JP2019081733A5 (fr) | ||
AU2017287987B2 (en) | Cartilage regeneration facilitating composition | |
JP7531261B2 (ja) | インターロイキン-23産生促進用組成物 | |
CN115137074A (zh) | 婴幼儿用排便促进剂 | |
NZ526544A (en) | Novel Probiotic Strain and Compositions | |
WO2011025019A1 (fr) | Bactérie lactique présentant une activité induisant la thiorédoxine et aliments, boissons et médicaments pour prévenir et/ou améliorer un dommage biologique par l'intermédiaire de la thioredoxine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18753719 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018568622 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18753719 Country of ref document: EP Kind code of ref document: A1 |